Cellistic
Mont-Saint-Guibert, Belgium
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cellistic
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Mont-Saint-Guibert, Belgium
- Modalities
- iPSC, CAR-T (iPSC-derived), NK cells (iPSC-derived), Cardiomyocytes (iPSC-derived), T cells (iPSC-derived)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesiPSC, CAR-T (iPSC-derived), NK cells (iPSC-derived), Cardiomyocytes (iPSC-derived), T cells (iPSC-derived)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction - Drug Target Review
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Business Wire
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies - pharmatimes.com
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - BioInformant
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - BioInformant
Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions - Business Wire
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development - BioInformant
BrightPath and Cellistic partner for trials of CAR-T cell therapy - Clinical Trials Arena
Cellistic Reveals Groundbreaking iPSC-based Platforms to Accelerate Off-the-shelf Allogeneic Cell Therapy Development and Manufacturing - biospace.com
Cellistic Reveals Groundbreaking iPSC-based Platforms to Accelerate Off-the-shelf Allogeneic Cell Therapy Development and Manufacturing - Business Wire
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: